Regimen Reference Order – LEUK – AL4 (Continuation)

ARIA: LEUK - [AL4 (Continuation)]

Planned Course: **1 cycle = 21 days**
Repeat Continuation Therapy until the total duration of therapy is 2 years from the date of Complete Remission

Indication for Use: **Acute Lymphoblastic Leukemia**

CVAD: Preferred (VESICANT INVOLVED)

Proceed with treatment if:

Cycle 1 Day 1

- ***ANC equal to or greater than 1 x 10^9/L AND Platelets equal to or greater than 100 x 10^9/L***
- ***AST less than 8 times the upper limit of normal***
- ***Direct bilirubin less than 25 µmol/L***

Cycle 2 and Onwards Day 1

- ***ANC equal to or greater than 0.5 x 10^9/L AND Platelets equal to or greater than 75 x 10^9/L***
- ***AST less than 8 times the upper limit of normal***
- ***Direct bilirubin less than 25 µmol/L***
  - ❖ **Contact Leukemia/BMT (L/BMT) Physician if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – LEUK – AL4 (Continuation)

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
dexamethasone	6 mg/m^2/day (round to nearest 2 mg)	Orally divided twice a day with food on **Days 1 to 5** **(Self-administered at home)**
vinCRIStine	2 mg (standard dose)	IV in normal saline 25 mL over 2 to 3 minutes by gravity infusion on **Day 1**
mercaptopurine	50 mg/m^2 (round to nearest 25 mg)	Orally once daily on an empty stomach **on Days 1 to 14** Do not take with milk or milk-based products **(Self-administered at home)**
methotrexate	60 mg/m^2	Orally once weekly on Days **2, 9 and 16** Take on an empty stomach **(Self-administered at home)**

Patients will receive Triple Intrathecal Therapy every 18 weeks while receiving continuation therapy

(Patient is placed on support regimen – LEUK – [AL4 (IT)] beginning with CNS phase which occurs every 126 days = 18 weeks). Intrathecal is given at the start of treatment cycles where possible. Refer to Appendix A

mercaptopurine (PURINETHOL®) available dosage strength: 50 mg tablets
Classification: Cytotoxic, Hazardous

methotrexate available dosage strength: 2.5 mg tablets
Classification: Cytotoxic, Hazardous

In the event of an infusion-related hypersensitivity reaction, refer to the '**Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

AL4 (Continuation)
Day 1

- CBC and biochemistry as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
sulfamethoxazole-trimethoprim DS	800/160mg	Orally twice daily on Saturdays and Sundays only

DISCHARGE INSTRUCTIONS

- If nausea or mucositis develops, instruct patient to contact their L/BMT physician
- sulfamethoxazole-trimethoprim should not be administered on intrathecal therapy days due to potential drug interaction
- mercaptopurine should not be taken at the same time as milk or milk-based products. Cow's milk in particular, contains high concentrations of xanthine oxidase which inactivates mercaptopurine
- Reinforce safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- Intrathecal therapy is part of this regimen and is given every 18 weeks. See APPENDIX A AL4 (IT)
- Dose adjustments are made to methotrexate and mercaptopurine to achieve a desired nadir ANC of 0.5 x 10^9/L to 0.75 x 10^9/L and platelets of 75 x 10^9/L to 100 x 10^9/L
- Treatment may be delayed if patient is experiencing moderate or severe mucositis
- If patient has recurrent mouth sores, they may be evaluated for HSV and considered for valacyclovir prophylaxis

APPENDIX A

LEUK – AL4 (IT)

Planned course: Every 18 weeks from the beginning of CNS Phase. Continue until the completion of AL4 (Continuation)

Proceed with treatment if:

- ***ANC equal to or greater than 0.5 x 10^9/L AND Platelets equal to or greater than 50 x 10^9/L***
  - ❖ **Contact L/BMT Physician if parameters not met**

Drug and Dose	CCMB Administration Guideline
Every 18 weeks (Starting with beginning of CNS phase)	
Triple Intrathecal: methotrexate 12 mg cytarabine 40 mg hydrocortisone 50 mg	Intrathecal in 6 mL preservative free normal saline administered in L/BMT Clinic

IT is ordered as a separate cyclical Support regimen LEUK – [AL4 (IT)]